A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

I8Q-MC-GSEA -

The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.

Trial Summary

Age Range
18 - 70 years
Conditions the trial is for
Dyslipidemias
What the trial is testing?
Atorvastatin, LY3202328, Simvastatin
Could I receive a Placebo?
Yes
Enrollment Goal
60
Trial Dates
Mar 1, 2016 - Feb 15, 2017
How long will I be in the trial?
Your participation could last up to 9 weeks and include up to two 4 day stays at the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.